High expression of SMARCE1 predicts poor prognosis and promotes cell growth and metastasis in gastric cancer

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.2126225651787
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388(10060):2654–2664. doi:10.1016/S0140-6736(16)30354-327156933
   PubMed Web of Science ®Google Scholar
• Zong L, Abe M, Seto Y, Ji J. The challenge of screening for early gastric cancer in China. Lancet. 2016;388(10060):2606. doi:10.1016/S0140-6736(16)32226-727894662
   PubMed Web of Science ®Google Scholar
• Clapier CR, Iwasa J, Cairns BR, Peterson CL. Mechanisms of action and regulation of ATP-dependent chromatin-remodelling complexes. Nat Rev Mol Cell Biol. 2017;18(7):407–422. doi:10.1038/nrm.2017.2628512350
   PubMed Web of Science ®Google Scholar
• Risinger MA, Groden J. Crosslinks and crosstalk: human cancer syndromes and DNA repair defects. Cancer Cell. 2004;6(6):539–545. doi:10.1016/j.ccr.2004.12.00115607958
   PubMed Web of Science ®Google Scholar
• Wood RD. Fifty years since DNA repair was linked to cancer. Nature. 2018;557(7707):648–649. doi:10.1038/d41586-018-05255-129844546
   PubMedGoogle Scholar
• Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol. 2003;21(6):1174–1179. doi:10.1200/JCO.2003.04.06012637487
   PubMed Web of Science ®Google Scholar
• Schaniel C, Ang YS, Ratnakumar K, et al. Smarcc1/Baf155 couples self-renewal gene repression with changes in chromatin structure in mouse embryonic stem cells. Stem Cells. 2009;27(12):2979–2991. doi:10.1002/stem.22319785031
   PubMed Web of Science ®Google Scholar
• Yoo AS, Staahl BT, Chen L, Crabtree GR. MicroRNA-mediated switching of chromatin-remodelling complexes in neural development. Nature. 2009;460(7255):642–646. doi:10.1038/nature0813919561591
   PubMed Web of Science ®Google Scholar
• Hang CT, Yang J, Han P, et al. Chromatin regulation by Brg1 underlies heart muscle development and disease. Nature. 2010;466(7302):62–67. doi:10.1038/nature0913020596014
   PubMed Web of Science ®Google Scholar
• Roberts CWM, Orkin SH. The SWI/SNF complex — chromatin and cancer. Nat Rev Cancer. 2004;4(2):133–142. doi:10.1038/nrc127314964309
   PubMed Web of Science ®Google Scholar
• Wilson BG, Roberts CWM. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer. 2011;11(7):481–492. doi:10.1038/nrc306821654818
   PubMed Web of Science ®Google Scholar
• Marazzi I, Greenbaum BD, Low DHP, Guccione E. Chromatin dependencies in cancer and inflammation. Nat Rev Mol Cell Biol. 2017;19(4):245–261. doi:10.1038/nrm.2017.11329184195
   PubMed Web of Science ®Google Scholar
• Rosson GB, Bartlett C, Reed W, Weissman BE. BRG1 loss in MiaPaCa2 cells induces an altered cellular morphology and disruption in the organization of the actin cytoskeleton. J Cell Physiol. 2005;205(2):286–294. doi:10.1002/(ISSN)1097-465215887247
   PubMed Web of Science ®Google Scholar
• Mathur R, Alver BH, San RA, et al. ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice. Nat Genet. 2017;49(2):296–302. doi:10.1038/ng.374427941798
   PubMed Web of Science ®Google Scholar
• Hah N, Kolkman A, Ruhl DD, et al. A role for BAF57 in cell cycle-dependent transcriptional regulation by the SWI/SNF chromatin remodeling complex. Cancer Res. 2010;70(11):4402–4411. doi:10.1158/0008-5472.CAN-09-276720460533
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Kurita T, Nishio K, et al. Expression of BAF57 in ovarian cancer cells and drug sensitivity. Cancer Sci. 2015;106(4):359–366. doi:10.1111/cas.1261225611552
   PubMed Web of Science ®Google Scholar
• Balasubramaniam S, Comstock CES, Ertel A, et al. Aberrant BAF57 signaling facilitates prometastatic phenotypes. Clin Cancer Res. 2013;19(10):2657–2667. doi:10.1158/1078-0432.CCR-12-304923493350
   PubMed Web of Science ®Google Scholar
• Link KA, Balasubramaniam S, Sharma A, et al. Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity. Cancer Res. 2008;68(12):4551–4558. doi:10.1158/0008-5472.CAN-07-639218559499
   PubMed Web of Science ®Google Scholar
• Papadakis AI, Sun C, Knijnenburg TA, et al. SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer. Cell Res. 2015;25(4):445–458. doi:10.1038/cr.2015.1625656847
   PubMed Web of Science ®Google Scholar
• Tauziede-Espariat A, Parfait B, Besnard A, et al. Loss of SMARCE1 expression is a specific diagnostic marker of clear cell meningioma: a comprehensive immunophenotypical and molecular analysis. Brain Pathol. 2018;28(4):466–474. doi:10.1111/bpa.1252428474749
   PubMed Web of Science ®Google Scholar
• Smith MJ, O’Sullivan J, Bhaskar SS, et al. Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nat Genet. 2013;45(3):295–298. doi:10.1038/ng.255223377182
   PubMed Web of Science ®Google Scholar
• Xiao S, Chang R, Yang M, et al. Actin-like 6A predicts poor prognosis of hepatocellular carcinoma and promotes metastasis and epithelial-mesenchymal transition. Hepatology. 2016;63(4):1256–1271. doi:10.1002/hep.2841726698646
   PubMed Web of Science ®Google Scholar
• Kagami S, Kurita T, Kawagoe T, et al. Prognostic significance of BAF57 expression in patients with endometrial carcinoma. Histol Histopathol. 2012;27(5):593–599. doi:10.14670/HH-27.59322419023
   PubMed Web of Science ®Google Scholar
• Sethuraman A, Brown M, Seagroves TN, Wu Z, Pfeffer LM, Fan M. SMARCE1 regulates metastatic potential of breast cancer cells through the HIF1A/PTK2 pathway. Breast Cancer Res. 2016;18(1):81. doi:10.1186/s13058-016-0738-927495308
   PubMedGoogle Scholar
• Kiskinis E, García-Pedrero JM, Villaronga MA, Parker MG, Belandia B. Identification of BAF57 mutations in human breast cancer cell lines. Breast Cancer Res Treat. 2006;98(2):191–198. doi:10.1007/s10549-005-9149-916538531
   PubMed Web of Science ®Google Scholar
• Davis LM, Harris C, Tang L, et al. Amplification patterns of three genomic regions predict distant recurrence in breast carcinoma. J Mol Diagn. 2007;9(3):327–336. doi:10.2353/jmoldx.2007.06007917591932
   PubMed Web of Science ®Google Scholar
• Má V, López-Mateo I, Markert L, Espinosa E, Já FV, Belandia B. Identification and characterization of novel potentially oncogenic mutations in the human BAF57 gene in a breast cancer patient. Breast Cancer Res Treat. 2011;128(3):891–898. doi:10.1007/s10549-011-1492-421465167
   PubMed Web of Science ®Google Scholar
• Sokol ES, Feng Y, Jin DX, et al. SMARCE1 is required for the invasive progression of in situ cancers. Proc Natl Acad Sci USA. 2017;114(16):4153–4158. doi:10.1073/pnas.170393111428377514
   PubMed Web of Science ®Google Scholar
• Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147(2):275–292. doi:10.1016/j.cell.2011.09.02422000009
   PubMed Web of Science ®Google Scholar
• Hayashi J, Aoki H, Kajino K, Moriyama M, Arakawa Y, Hino O. Hepatitis C virus core protein activates the MAPK/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor or transforming growth factor alpha. Hepatology. 2000;32(5):958–961. doi:10.1053/jhep.2000.1934311050045
   PubMed Web of Science ®Google Scholar
• Wu S, Lao X, Sun T, et al. Knockdown of ZFX inhibits gastric cancer cell growth in vitro and in vivo via downregulating the ERK-MAPK pathway. Cancer Lett. 2013;337(2):293–300. doi:10.1016/j.canlet.2013.04.00323587796
   PubMed Web of Science ®Google Scholar